Reports Outline Cancer Findings from Roswell Park Comprehensive Cancer Center (Platelet-activating Factor: a Potential Therapeutic Target To Improve Cancer Immunotherapy).

The research conducted at Roswell Park Comprehensive Cancer Center in Buffalo, New York, focuses on the role of platelet-activating factor (PAF) in the tumor microenvironment (TME) and its impact on cancer immunotherapy. The study suggests that inhibiting PAF signaling could enhance cytotoxic T-cell activity by reducing myeloid-derived suppressor cell (MDSC)-mediated immunosuppression. This approach shows promise in improving cancer immunotherapy outcomes, especially when combined with checkpoint blockade therapies. For more information, readers can refer to the article "Platelet-activating Factor: a Potential Therapeutic Target To Improve Cancer Immunotherapy" published in Molecular Oncology. [Extracted from the article]